Detronin 5mg/5ml

Oxybutynin 5mg

Gastric or urinary obstruction or retention, paralytic ileus, severe ulcerative colitis
Uncontrolled narrow-angle glaucoma
Relative contraindications: Myasthenia gravis, tachycardia secondary to cardiac insufficiency or thyrotoxicosis

Caution in controlled angle-closure glaucoma; mild-to-moderate ulcerative colitis, hyperthyroidism; partial obstructive uropathy; benign prostatic hyperplasia
Caution in hepatic or renal impairment
May increase risk of heat prostration during hot weather
May cause memory loss
Angioedema necessitating hospitalization and emergency medical treatment has occurred with first or subsequent doses of oral oxybutynin; if angioedema develops, oxybutynin-containing products should be discontinued and appropriate therapy promptly provided
Caution with gastrointestinal obstructive disorders or decreased intestinal motility because of the risk of gastric retention
May aggravate symptoms of decreased gastrointestinal motility in patients with autonomic neuropathy
Caution with GERD and/or those taking drugs that can cause or exacerbate esophagitis (eg, bisphosphonates)
Caution with myasthenia gravis because of decreased cholinergic activity
Caution with other anticholinergics (antimuscarinics); may increase risk for xerostomia, constipation, headache, dizziness, and blurred vision
Somnolence reported with oxybutynin-containing products; use caution with activities requiring mental alertness
May aggravate Parkinson disease symptoms
Hallucinations or confusion may occur; monitor
May exacerbate symptoms of heart failure, hypertension, and/or cardiac arrhythmias; use with caution
May aggravate symptoms of dementia in patients cholinesterase inhibitors; use with caution
Use with caution in patients with hiatal hernia
The use of the extended release formulation has been associated (rare) with symptoms of obstruction in patients with known stricture/narrowing of the GI tract
Before using over the counter product, consider other causes of frequent urination, including early pregnancy, diabetes, and other serious conditions; contact healthcare provider if symptoms do not improve with 2 weeks of initial use
Avoid use in patients with myasthenia gravis because of decreased cholinergic activity; if experiencing exacerbation of symptoms of myasthenia gravis, oxybutynin-containing product should be discontinued and appropriate therapy promptly provided

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use Detronin 5mg/5ml only for the indication prescribed.